Kathrine Gamborg Andreassen
Kathrine Gamborg Andreassen was elected Chair of the Board June 2018. Kathrine is an experienced marketing professional and has held various executive positions in Consumer Health and FmCG (Orkla, Kemetyl). She held the position as the Chief Executive Officer at Weifa ASA until the company was acquired by Karo Pharma AB November 2017, and prior to that VP Consumer Health at Weifa AS. She has several years of experience as a consultant in strategy and marketing research . She was also co-owner and the Chair of the Board at Novicus Pharma AS. Gamborg Andreassen studied Business Administration (BBA) at Handelsakademiet/ Oslo Business School and holds a MSc in Business Strategy & Marketing from the University of Wisconsin, Madison.
Lars has spent approximately 15 years in the US, first earning Bachelor and MBA degrees in Economics and Finance respectively and subsequently working for different US based companies until 2008. Since 2008 he has lived and worked in Norway, first as a Chief Group Controller in a listed Norwegian company and then in Lindorff Group. In 2010 he was appointed CFO for the Norwegian Lindorff operation and has been interim Group CFO on two occasions. Upon the merger of Lindorff and Intrum, Lars joined the carve-out business as CFO which in 2018 became the Nordic Region of Lowell Group.
Ole Henrik Eriksen
Position: COO, Business Development
Ole Henrik Eriksen has extensive experience from the pharma, biotech, diagnostics and medtech industries. Previous experience includes VP CMC in Nycomed Imaging, VP Business Development in Medinnova, CEO and COO in Clavis Pharma ASA, COO and responsible for Business Development in Weifa ASA and Chairman of Genetic Analysis AS. He was also one of the three founders of Novicus Pharma AS, now acquired by Navamedic ASA. Mr. Eriksen holds a B.Sc. in Organic Chemistry from the Norwegian University of Sciences and Technology in Trondheim.
Position: Director Market Access & Operations
Date of birth: 07.06.1974
2010- CSO Navamedic ASA
Per-Anders has more than 15 years’ experience working in regulatory affairs and management positions in the pharmaceutical industry. Prior to joining Navamedic Per-Anders was working for Sandoz GmbH in Germany as Head of Regulatory Competence Center for Asia-Pacific region. Previous experience includes being Regulatory Affairs Manager for Sandoz in Australia and Nordic Regulatory Affairs Manager for Sandoz/Hexal in Denmark. Per-Anders Elvertrø holds a Master of Science in Biology from Norwegian University of Science and Technology, Trondheim. Mr. Elvertrø holds 30 000 shares in the Company.
Astrid T. Bratvedt
Position: Chief Scientific Officer
Astrid T. Bratvedt has extensive pharmaceutical experience within regulatory and medical affairs and quality assurance of medicinal- and consumer health products.
She started her career in Weifa AS in 1990 with Regulatory- and Medical positions. She was VP R&D since 2009 and later Chief Scientific Officer.
Her work resulted in numerous OTC switches and first to market OTC products.
She was also one of the three founders of Novicus Pharma AS, now acquired by Navamedic ASA.Astrid holds a Master of Science in Pharmacy from University of Oslo.
Position: Sales Director
Date of birth: 1981
Alexander joined Navamedic 2010 and has been responsible for the area Medical Nutrition and since 2017 Sales manager for Denmark & Norway. Alexander holds a Bachelor degree in Dietetics and Science and studies in Business Management from IHM Business school.
Position: Country Manager Finland